A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

Completed · Has a placebo group

Conditions studied: Healthy, Hepatitis C

In brief

The purpose of this study is to determine the rate of kidney or heart impairment, if any, in subjects who received BMS-986094 (INX-08189) in Phase 1 clinical trials

Key facts

Study ID

NCT01732848

Run by

Bristol-Myers Squibb

People needed

113

Starts

2012-11-01

Expected to finish

2014-06-01

Last updated by the study team

2014-08-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy and hepatitis C virus (HCV)-infected subjects who participated in prior Phase 1 trial with BMS-986094/INX-08189 and:
• Received at least 1 dose of INX-08189 or
• Received placebo in studies for HCV-infected subjects (INH-189-002 or INH-189-006)
• Age 18 or older

Where it is running

• Local Institution — Los Angeles, California, United States
• Prism Research — Saint Paul, Minnesota, United States
• New Orleans Center For Clinical Research - Knoxville — Knoxville, Tennessee, United States
• Local Institution — San Antonio, Texas, United States
• Local Institution — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.